Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Disease of the Month – Alopecia 
Shots: Hair loss (alopecia) is a condition that causes thinning or loss of hair on the scalp or the entire body. It can be temporary or permanent and may result from genetics, hormonal changes, medical issues, or aging   PharmaShots’ Disease of the Month report aims to educate a broad audience about health conditions that affect…
September 30, 2025
New Drug Designations – August 2025     
Shots:     PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA   The August 2025 report covers designations granted to 37 drugs and 4 medical devices, spanning 14 small molecules, 5 biologics, 7 cell and gene therapies & 4 medical devices, among others   Significant…
September 23, 2025
EMA Marketing Authorization of New Drugs in August 2025
Shots: The EMA’s CHMP has granted approvals to 1 Biologic and 3 new chemical entities in August 2025, leading to treatments for patients and advances in the healthcare industry  The major highlighted drug was Gilead’s Yeytuo has Secured the EC’s Approval for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV   PharmaShots has compiled a list of 4…
September 16, 2025
The US FDA New Drug Approvals in August 2025  
Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of August 2025 The US FDA has approved a total of 5 new drugs, including 5 new molecular entities, leading to the treatment of patients and advances in the pharmaceutical industry The major highlighted drug was Jazz Pharmaceuticals’ Modeyso, securing FDA approval…
September 9, 2025
Know Your Investor: Cormorant Asset Management (September’25 Edition) 
Shots: Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…
September 4, 2025
Key Biosimilars Events of August 2025  
Shots:       Biosimilars are developed to be highly similar of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        Alvotech and Advanz Pharma Receive the EC’s Approval for Mynzepli (Biosimilar, Eylea). Our…
September 2, 2025
Disease of the Month – Rosacea 
Shots: Rosacea is a chronic skin condition characterized by facial redness, acne-like breakouts, and flushing. It may cause enlarged blood vessels and small pus pus-filled bumps  PharmaShots’ Disease of the Month report aims to educate a broad audience about health conditions that affect communities worldwide. These reports provide a comprehensive overview of disease, including their…
August 27, 2025
New Drug Designations: July 2025
New Drug Designations: July 2025
Shots:      PharmaShots’ Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA.   The July 2025 edition covers designations awarded to 47 drugs and 3 medical devices, comprising 23 small molecules, 9 biologics, 8 cell and gene therapies, and…
August 26, 2025
EMA Marketing Authorization of New Drugs in July 2025  
Shots: The EMA’s CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the healthcare industry  The major highlighted drug was Roche’s Itovebi Secures the EC’s Approval for PIK3CA-mutated Breast Cancer   PharmaShots has compiled a list of 13 drugs…
August 19, 2025
The US FDA New Drug Approvals in July 2025  
Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of July 2025 The US FDA has approved a total of 6 new drugs, including 5 new molecular entities and 1 biologic, leading to the treatment of patients and advances in the pharmaceutical industry The major highlighted drug was Regeneron’s Lynozyfic, securing…
August 12, 2025
Load more